Related Experiment Video
Updated: Jun 29, 2026

08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.6K
Robust Four-Field and Arc LET-Optimized Proton Prostate Cancer Treatment Plans With Urethral Sparing
Michael Vieceli1,2, Jiyeon Park1,2, Mo Saki1,2
1University of Florida Health Proton Therapy Institute, Jacksonville, FL 32206, USA.
International Journal of Particle Therapy
|May 1, 2026
Summary
LET-optimized proton therapy plans for prostate cancer improve treatment by increasing high Linear Energy Transfer (LET) dose to tumors while sparing the urethra. These plans offer better robustness and potentially enhance the therapeutic ratio.
Area of Science:
- Radiation Oncology
- Medical Physics
- Proton Therapy
Background:
- Proton therapy utilizes pencil beam scanning for precise dose delivery.
- Optimizing Linear Energy Transfer (LET) can enhance the biological effectiveness of proton therapy.
- Urethral sparing is crucial in prostate cancer treatment to minimize side effects.
Purpose of the Study:
- To develop LET-optimized pencil beam scanning proton therapy plans for prostate cancer.
- To achieve clinically acceptable range robustness and effective urethral sparing.
- To evaluate the trade-offs between robustness, LET, and dose distribution.
Main Methods:
- Creation of two-beam, four-beam, and arc LET-optimized treatment plans.
- Incorporation of urethral sparing by reducing physical dose to the urethra.
- Statistical comparison of LETd, RBE-doses, TODRs, and V80% between LET-optimized and reference SFO plans across 12 patients.
Main Results:
- LET-optimized plans demonstrated a trade-off between robustness and high LETd.
- Four-beam and arc plans showed statistically significant increases in CTV PSV-U D95 RBE-dose compared to SFO plans.
- High LETd in the periurethral prostate prevented underdosage, achieving urethral sparing; V80%s were decreased in four-beam and arc plans.
Conclusions:
- LET-optimized treatment plans achieve high LETd and clinical robustness for prostate cancer.
- These plans have the potential to increase the therapeutic ratio.
- Urethral sparing is implemented effectively without underdosing the periurethral prostate.

